GB0418435D0 - HDAC inhibitors and methods of use thereof - Google Patents

HDAC inhibitors and methods of use thereof

Info

Publication number
GB0418435D0
GB0418435D0 GBGB0418435.4A GB0418435A GB0418435D0 GB 0418435 D0 GB0418435 D0 GB 0418435D0 GB 0418435 A GB0418435 A GB 0418435A GB 0418435 D0 GB0418435 D0 GB 0418435D0
Authority
GB
United Kingdom
Prior art keywords
methods
hdac inhibitors
hdac
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB0418435.4A
Other versions
GB2417682A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of East Anglia
Original Assignee
University of East Anglia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of East Anglia filed Critical University of East Anglia
Priority to GB0418435A priority Critical patent/GB2417682A/en
Publication of GB0418435D0 publication Critical patent/GB0418435D0/en
Priority to PCT/GB2005/003256 priority patent/WO2006018657A1/en
Publication of GB2417682A publication Critical patent/GB2417682A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GB0418435A 2004-08-18 2004-08-18 Histone deacetylse inhibitor for treating connective tissue disorders Withdrawn GB2417682A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB0418435A GB2417682A (en) 2004-08-18 2004-08-18 Histone deacetylse inhibitor for treating connective tissue disorders
PCT/GB2005/003256 WO2006018657A1 (en) 2004-08-18 2005-08-18 Hdac inhibitors and methods of use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0418435A GB2417682A (en) 2004-08-18 2004-08-18 Histone deacetylse inhibitor for treating connective tissue disorders

Publications (2)

Publication Number Publication Date
GB0418435D0 true GB0418435D0 (en) 2004-09-22
GB2417682A GB2417682A (en) 2006-03-08

Family

ID=33042261

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0418435A Withdrawn GB2417682A (en) 2004-08-18 2004-08-18 Histone deacetylse inhibitor for treating connective tissue disorders

Country Status (2)

Country Link
GB (1) GB2417682A (en)
WO (1) WO2006018657A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0612273D0 (en) * 2006-06-21 2006-08-02 Friedrich Miescher Inst For Bi Prevention of muscle atrophy
US8377875B2 (en) 2007-01-11 2013-02-19 Ramot At Tel-Aviv University Ltd. Therapeutics based on tau/microtubule dynamics
DE102008047515A1 (en) * 2008-09-12 2010-03-25 Eberhard-Karls-Universität Tübingen Universitätsklinikum Use of histone deacetylase inhibitor for the preparation of a medicament for prophylaxis and/or treatment of demyelinating disease, preferably autoimmune neuropathy, Guillain-Barre syndrome, acute inflammatory demyelinating polyneuropathy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20011733A1 (en) * 2001-08-07 2003-02-07 Italfarmaco Spa HYDROXAMIC ACID DERIVATIVES HISTONE DEHYACETYLASE ENZYM INHIBITORS, WHICH NEW ANTI-INFLAMMATORY DRUGS INHIBIT CITOC SYNTHESIS
AU2003226014A1 (en) * 2002-03-28 2003-10-13 Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
ATE399012T1 (en) * 2002-04-03 2008-07-15 Topotarget Uk Ltd CARBAMINIC ACID DERIVATIVES CONTAINING A PIPERAZINE LINKAGE AS HDAC INHIBITORS
US20030206946A1 (en) * 2002-04-26 2003-11-06 Yih-Lin Chung Methods for therapy of connective tissue disease
EP1547617B1 (en) * 2002-08-20 2010-04-28 Astellas Pharma Inc. Arthrodial cartilage extracellular matrix degradation inhibitor
KR20050074547A (en) * 2002-11-12 2005-07-18 알콘, 인코퍼레이티드 Histone deacetylase inhibitors for treating degenerative diseases of the eye

Also Published As

Publication number Publication date
GB2417682A (en) 2006-03-08
WO2006018657A1 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
HRP20182133T1 (en) Compositions comprising azelastine and methods of use thereof
IL213843A0 (en) 4-aminotetracyclines and methods of use thereof
IL176958A0 (en) Compounds and methods of use
EP1931205A4 (en) Transglutaminase inhibitors and methods of use thereof
EP1940787A4 (en) Novel ido inhibitors and methods of use thereof
AU2003303128A8 (en) Inhibitors and methods of use thereof
EP1827391A4 (en) Dosage forms and methods of use thereof
ZA200802822B (en) Raf inhibitor compounds and methods of use thereof
ZA200710969B (en) Raf inhibitor compounds and methods of use thereof
IL178593A (en) Fcγriib-specific antibodies and methods of use thereof
HK1162028A1 (en) Heterocyclic inhibitors of mek and methods of use thereof mek
IL185309A0 (en) Isoqunoline compounds and methods of use thereof
EP1691812A4 (en) Gtpase inhibitors and methods of use
EP1789437A4 (en) Npc1l1 and npc1l1 inhibitors and methods of use thereof
EP1812451A4 (en) Compounds and methods of use thereof
ZA200710218B (en) Mitotic kinesin inhibitors and methods of use thereof
EP1735281A4 (en) Synthesis of indenoisoquinoliniums and methods of use
EP1883404A4 (en) P38 inhibitors and methods of use thereof
IL186120A0 (en) Inhibitors of neurotrypsin and determination thereof
EP1682115A4 (en) Hif-1 inhibitors and methods of use thereof
GB0418435D0 (en) HDAC inhibitors and methods of use thereof
EP1978999A4 (en) Isolated mcpip and methods of use
EP1933820A4 (en) Palmarumycin based inhibitors of thioredoxin and methods of using same
ZA200710971B (en) Elasmobranch-repelling compounds and methods of use

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)